MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Home・Akcijų sąrašas・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

25.97 -1.7

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

25.73

Max

26.05

Pagrindiniai rodikliai
By Trading Economics
Pajamos	45M 72M
Pardavimai	14M 279M
P/E Sektoriaus vid.	17.155 90.831
Pelnas, tenkantis vienai akcijai	0.42
Pelno marža	25.761
Darbuotojai	653
EBITDA	7.3M 48M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+19.85% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-25

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	724M 4.5B
Ankstesnė atidarymo kaina	27.67
Ankstesnė uždarymo kaina	25.97

Naujienos nuotaikos

By Acuity

50%

158 / 361 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

14.845 / N/A Palaikymas ir pasipriešinimas

ACADIA Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-16 23:29; UTC

Karštos akcijos

Stocks to Watch: Atossa Therapeutics, Union Pacific

2026-01-17 15:06; UTC

Įsigijimai, susijungimai, perėmimai

Trump Purchased Netflix, Warner Bonds in Days After Deal Announcement -- Update

2026-01-17 10:30; UTC

Uždarbis

Supersize CEO Pay Packages Aren't Paying Off for Shareholders -- WSJ

2026-01-17 03:10; UTC

Įsigijimai, susijungimai, perėmimai

Trump Purchased Netflix, Warner Bonds In Days After Deal Announcement -- WSJ

2026-01-16 22:48; UTC

Įsigijimai, susijungimai, perėmimai

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

2026-01-16 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

2026-01-16 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

2026-01-16 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-01-16 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Auto & Transport Roundup: Market Talk

2026-01-16 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-16 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-16 21:48; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

2026-01-16 21:41; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

2026-01-16 21:38; UTC

Įsigijimai, susijungimai, perėmimai

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

2026-01-16 20:44; UTC

Uždarbis

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

2026-01-16 20:42; UTC

Rinkos pokalbiai

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

2026-01-16 20:28; UTC

Rinkos pokalbiai

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

2026-01-16 19:12; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

2026-01-16 18:53; UTC

Rinkos pokalbiai

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

2026-01-16 18:41; UTC

Rinkos pokalbiai

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

2026-01-16 18:31; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

2026-01-16 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-16 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-16 17:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-16 17:03; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

ACADIA Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

19.85% į viršų

12 mėnesių prognozė

Vidutinis 31.15 USD 19.85%

Aukščiausias 40 USD

Žemiausias 21 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines ACADIA Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

13 ratings

Pirkti

Laikyti

Parduoti

Remiantis 13 analitikų, pateikusių ACADIA Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

14.845 / N/APalaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

158 / 361 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.